Literature DB >> 8402458

The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer.

C K Høgdall1, L Christensen, I Clemmensen.   

Abstract

BACKGROUND: Tetranectin (TN), a tetrameric, plasminogen-binding protein, was reduced in the plasma of patients with cancer and appears extracellularly in "stimulated" connective tissues, such as the proliferative, connective tissue response to carcinomas known as desmoplasia.
METHODS: Tissue samples from 37 patients with ovarian cancer were examined immunohistochemically for stromal and cellular TN. Plasma samples obtained before the primary surgery were quantitated for TN. The univariate log-rank test and the multivariate Cox proportional hazards regression model were used to analyze the prognostic function of the variables.
RESULTS: A significantly higher survival rate was found for patients with a low-stromal TN score and a high-plasma TN concentration, whereas the cellular TN score did not have any significance. A significant negative correlation was found between plasma TN and stromal TN (RS = -0.36; P = 0.03). Independent significant correlations were found between stromal immunoreactivity for TN and tumor grade (R = 0.67; P = 0.03) and between plasma TN and tumor stage (R = -0.29; P = 0.01).
CONCLUSIONS: This study gives great expectations to TN as a useful parameter for prognostic evaluation of patients with ovarian cancer. According to the correlations, stromal TN may partly originate from plasma and enhance proteolytic degradation in the interstitial tissue, a process necessary for the spread and growth of cancer. Because plasma TN measurements are only valid when taken preoperatively, it is of great value that stromal TN immunoreactivity of stored tumor tissue can be used as a prognostic factor for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402458     DOI: 10.1002/1097-0142(19931015)72:8<2415::aid-cncr2820720820>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Tetranectin in slow intra- and extrafusal chicken muscle fibers.

Authors:  X Xu; B Gilpin; K Iba; A Maier; E Engvall; R Albrechtsen; U M Wewer
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

2.  Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer.

Authors:  A Brunner; C Ensinger; M Christiansen; S Heiss; I Verdorfer; G Mikuz; A Tzankov
Journal:  Virchows Arch       Date:  2007-04-13       Impact factor: 4.064

3.  Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity.

Authors:  K Iba; M E Durkin; L Johnsen; E Hunziker; K Damgaard-Pedersen; H Zhang; E Engvall; R Albrechtsen; U M Wewer
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

4.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

Authors:  P Obrist; G Spizzo; C Ensinger; D Fong; T Brunhuber; G Schäfer; M Varga; R Margreiter; A Amberger; G Gastl; M Christiansen
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

5.  CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.

Authors:  Jian Liu; Zhe Liu; Qun Liu; Lina Li; Xiaona Fan; Tao Wen; Guangyu An
Journal:  Oncol Rep       Date:  2018-07-23       Impact factor: 3.906

6.  Exosomal proteomic signatures correlate with drug resistance and carboplatin treatment outcome in a spontaneous model of canine osteosarcoma.

Authors:  Marcus A Weinman; Stephen A Ramsey; Haley J Leeper; Jacqueline V Brady; Andrew Schlueter; Stanislau Stanisheuski; Claudia S Maier; Tasha Miller; Carl E Ruby; Shay Bracha
Journal:  Cancer Cell Int       Date:  2021-05-01       Impact factor: 6.429

7.  Adipogenic function of tetranectin mediated by enhancing mitotic clonal expansion via ERK signaling.

Authors:  Seulgi Go; Jihyun Park; Safikur Rahman; Juno Jin; Inho Choi; Jihoe Kim
Journal:  BMB Rep       Date:  2021-07       Impact factor: 4.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.